- Stallergenes to exercise option to develop and commercialize a birch allergy new product
- DBV eligible for milestone payments and royalties on Stallergenes' net sales
- Stallergenes acquires an equity position in DBV
In conjunction with this agreement, Stallergenes acquires a 2.0% equity position in DBV from existing shareholders.Dr. Pierre-Henri Benhamou, Chairman and CEO of DBV Technologies, said: "We are pleased to partner with Stallergenes on this exciting respiratory development program using a recombinant Birch allergen protein. This reflects the broader potential of the Viaskin technology beyond only food allergies. Given Stallergenes' experience in immunotherapy and allergen development, coupled with DBV's epicutaneous delivery technology, this collaboration could lead to a valuable medical treatment for patients with respiratory allergies." Dr. Roberto Gradnik, CEO of Stallergenes, said: " This collaboration on birch allergy with DBV Technologies is the first concrete project combining our in-depth expertise in allergen immunotherapy with DBV's promising epicutaneous route of administration. Illustrating our continuous focus on innovation and patients' needs, it will provide a highly innovative solution for patients suffering from intense symptoms due to birch allergy." In 2003, Stallergenes licensed Biomay recombinant birch pollen protein technology. About Birch allergy Very common in Northern Europe - and especially Germany, the Netherlands, Norway, Sweden and Switzerland, the prevalence of allergic rhinitis caused by birch pollen affects between 10 and 20% of the northern and central European population and exceeds 20% in some large cities. Birch produces the most allergenic pollen among all trees in northern, central and eastern Europe The birch pollen season is short - lasting just 1 to 2 months - but intense, and precedes the grass pollen season. About DBV Technologies DBV Technologies is opening up a decisive new approach to the treatment of allergy - a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy - a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com CAUTION: Viaskin® is not approved for sale in the USA.
Forward Looking Statement related to DBV TechnologiesThe forward-looking statements, objectives and targets contained herein are based on the Company's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Company may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Company cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. DBV technologies' business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. About Stallergenes Stallergenes is an international biopharmaceutical company dedicated to the treatment of allergy-related respiratory diseases, such as severe rhinoconjunctivitis and rhinitis, as well as allergic asthma, using allergen immunotherapy. The leader in sublingual immunotherapy treatments, Stallergenes devotes around 20% of its annual gross sales to Research & Development and is actively involved in the development of a new therapeutic class: sublingual immunotherapy tablets. In 2012, the Company generated sales of € 240 million, and more than 500,000 patients were treated with Stallergenes products.
|Euronext Paris (Compartment B)|
CONTACT: Stallergenes: Stallergenes Investor and analyst relations: Peter Buhler Chief Financial Officer Tel. +33 1 55 59 20 95 e-mail: firstname.lastname@example.org Press Relations: Lise Lemonnier Senior Communication & Public Affairs Director Tel. + 33 1 55 59 20 96 e-mail: email@example.com Investor and press relations agency: FTI Consulting Analyst and investor contact Stephan Dubosq Tel. +33 1 47 03 68 16 firstname.lastname@example.org Press contact Jeanne Bariller Tel. +33 1 47 03 68 56 email@example.com DBV Technologies: DBV Technologies David Schilansky Chief Financial Officer Tel. : +33(0)1 55 42 78 75 firstname.lastname@example.org US & UK investors The Trout Group Investor Relations Alan S. Roemer Tel. : +1 (646) 378-2945 email@example.com French investors NewCap. Financial Communication and investor relations Emmanuel Huynh / Valentine Brouchot Tel. : +33(0)1 44 71 94 94 firstname.lastname@example.org US press & media Ronald Trahan, APR Press relations Ronald Trahan Tel. : +1 508 359 4005 email@example.com